Times shown are in EST

8:00 am Registration & Coffee

9:00 am Chair’s Opening Remarks

9:30 am Taking a Comparative Oncological Perspective to Understand the Significance of Neoantigens in Cancer Immunotherapy

  • Stanley Leong Professor Emeritus of Surgery, University of California, San Francisco School

10:00 am ImmunoID NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics & Profiling Tumor Heterogeneity

  • Christelle Johnson Senior Field Applications Scientist, Cancer Genomics & Immuno-Oncology, Personalis, Inc.

10:30 am Targeting ERAP1 to Alter the Cancer Immunopeptidome

  • Peter Joyce Chief Executive Officer, Co-Founder , Grey Wolf Therapeutics

11:00 am An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

  • Trevor Clancy Chief Scientific Officer & Co-Founder, OncoImmunity

11:30 am Speed Networking

12:00 pm Morning Refreshments

13:30 pm Lunch & Networking

15:30 pm Afternoon Break & Speed Networking

4:00 pm Using AI To Accelerate Immunotherapy In Cancer

4:30 pm Engineered T cells for the tTreatment of Malignancy

  • Jennie Lill Senior Director of Proteomics & NGS , Genentech

5:00 pm An Update on Neoantigen Vaccination for Glioblastoma

  • David Reardon Clinical Director, Center for NeuroOncology, Dana-Farber Cancer Institute

17:30 Chair’s Closing Remarks

6:10 pm End of Day 1